Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>The status of targeted genes and the association between targeted genes and clinicopathological features in Chinese lung cancer patients remains to be elucidated.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>The status of 10 targeted genes was evaluated by next‐generation sequencing (NGS) in 884 non‐small cell lung cancer (NSCLC) patients. The relationship between gene alterations and clinicopathological characters was analyzed.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Overall, 684 (77.4%) patients harbored gene alterations, and <i>EGFR </i> (510, 57.7%) was found to be the most common type of mutation followed by <i>KRAS </i> (91, 10.3%), <i>HER2 </i> (38, 4.3%), <i>PIK3CA </i> (32, 3.6%), <i>ALK </i> (21, 2.4%), <i>BRAF </i> (10, 1.1%), <i>ROS1 </i> (5, 0.6%), <i>RET </i> (5, 0.6%), <i>MET </i> (4, 0.5%) and <i>NRAS </i> (1, 0.1%) Gene alterations were more frequent in females, non‐smokers and adenocarcinoma (<i>P </i> < 0.001). <i>EGFR </i> mutations were associated with women, non‐smokers, normal level of serum tumor markers, and adenocarcinoma <i>(P </i> < 0.001). Patients without lymph node metastasis (<i>P </i> = 0.012), or early stage disease (<i>P </i> < 0.001) exhibited a higher <i>EGFR </i> mutation rate. <i>KRAS </i> mutations tended to arise in men (<i>P </i> < 0.001), smokers (<i>P </i> < 0.001) and patients with higher levels of serum tumor markers (<i>P </i> = 0.048). A mucus‐producing component was associated with <i>KRAS </i> (<i>P </i> < 0.001), <i>ROS1 </i> (<i>P </i> = 0.033) and <i>ALK </i> (<i>P </i> < 0.001) alterations. <i>ALK </i> and <i>ROS1 </i> rearrangements were more frequent in micropapillary structures (<i>P </i> = 0.004, <i>P </i> = 0.012). <i>BRAF </i> mutation was associated with advanced disease patients and micropapillary structure (<i>P </i> < 0.001). <i>PIK3CA </i> mutation was more likely to be found in elderly patients (<i>P </i> = 0.014). Some patients had synchronous gene alterations, including <i>EGFR/PIK3CA </i>, <i>EGFR/HER2 </i>, <i>HER2/KRAS </i>, <i>EGFR/KRAS </i>, <i>EGFR/ROS1 </i>, <i>EGFR/NRAS </i>, <i>KRAS/PIK3CA </i>, <i>KRAS/PIK3CA/HER2. </i></p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Most patients had at least one genetic alteration, and individual patients harbored synchronous mutation. Each gene alteration had unique clinicopathological characteristics.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key points</h3></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Significant findings of the study</h3><p>This study revealed the frequency and distribution of 10 targeted gene abnormalities and their association with clinicopathological parameters of Chinese non‐small cell lung cancer (NSCLC) patients in eastern China.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> What this study adds</h3><p>Some rare synchronous mutations were detected in our study by next‐generation sequencing (NGS).</p></section>

Correlation Between Ctdna Mutation and Clinicopathological Features of Peripheral Blood in Patients with Lung Cancer Based on Next-Generation Sequencing

Clinical significance of multi-sample next-generation sequencing for detection of gene mutations in non-small cell lung cancer

Clinicopathological Significance of Next-Generation Sequencing Technology for Detection of Gene Mutations in Lung Cancer Tissues

Correlation Analysis Between Driver Gene Mutation and Clinicopathological Features in Lung Adenocarcinoma Based on Real-World Cumulative Clinical Data

Analysis of Common Mutations in Non-Small Cell Lung Cancer by High-Throughput Sequencing

Comparative study on the mutation spectrum of tissue DNA and blood ctDNA in patients with non-small cell lung cancer

Gene Alternation of Cerebrospinal Fluid in Patients with Leptomeningeal Metastases of Lung Adenocarcinoma Using Next-Generation Sequencing

Targeted Next-Generation Sequencing of 491 Lung Cancers in Clinical Practice: Implications for Future Detection Strategy and Targeted Therapy

Next-generation Sequencing-Based Identification of EGFR and NOTCH2 Complementary Mutations in Non-Small Cell Lung Cancer

Correlation between gene mutation status and clinicopathologic features in early multiple primary lung cancer

The Utilization of Next-Generation Sequencing to Detect Somatic Mutations and Predict Clinical Prognosis of Chinese Non-Small Cell Lung Cancer Patients

P2.01-107 Analysis of Mutation Detection by Ctdna on the Basis of Metastatic Sites in Lung Adenocarcinoma Patients

The Co-Mutation of EGFR and Tumor-Related Genes Leads to a Worse Prognosis and a Higher Level of Tumor Mutational Burden in Chinese Non-Small Cell Lung Cancer Patients

Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer.

Catalog of Lung Cancer Gene Mutations Among Chinese Patients

The Unique Genetic Mutation Characteristics Based on Large Panel Next-Generation Sequencing (NGS) Detection in Multiple Primary Lung Cancers (MPLC) Patients

The Relationship Between Different Subtypes of KRAS and PD-L1 & Tumor Mutation Burden (TMB) Based on Next-Generation Sequencing (NGS) Detection in Chinese Lung Cancer Patients

Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution

Utility of Circulating Tumor DNA Assay in Identifying Mutations and Guiding Matched Targeted Therapy in Lung Cancers

[Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].

P1.01-035 A Next Generation Sequencing and Characteristics Based Model for Predict Clinical Benefits of Advanced NSCLC Patients